Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

PURCHASE, NY, April 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 (“First Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 (“First Quarter 2023”).

Teladoc Health Reports First Quarter 2024 Results

Teladoc (NYSE: TDOC) stock price has been one of the worst performers in Wall Street in the past few years. It peaked at $307 in 2021 as most Americans embraced telehealth services.

Teladoc (TDOC) stock price analysis and the fall from grace

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

NEW YORK, NY / ACCESSWIRE / April 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

ATTENTION Teladoc Health, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Teladoc's business peaked during the early days of the pandemic but has been struggling since. The company does have several things going its way, including a long runway in its industry.

Should You Buy This Beaten-Down Stock?

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

TDOC STOCK ALERT: Levi & Korsinsky Notifies Teladoc Health, Inc. Investors of an Ongoing Investigation

Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for

In the latest trading session, Teladoc (TDOC) closed at $13.14, marking a +0.08% move from the previous day.

Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know

Blade Air Mobility

Pacific Biosciences of California

Roku

At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors.

The Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's Leaving

NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Shareholders that lost money on Teladoc Health, Inc.(TDOC) should contact Levi & Korsinsky about Securities Fraud Investigation - TDOC

PURCHASE, NY, April 15, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that the conference call to review its first quarter 2024 results, previously scheduled for 4:30 p.m. E.T. on April 25, 2024, will now start at 5:00 p.m. E.T. on that same day.

Teladoc Health Provides Updated Start Time for First Quarter 2024 Earnings Call on April 25

NEW YORK, NY / ACCESSWIRE / April 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Teladoc Health, Inc. (TDOC) Regarding Possible Securities Fraud Violations

PURCHASE, NY, April 12, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release first quarter 2024 results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Teladoc Health to Announce First Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

TDOC ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Teladoc Health, Inc.

Intellia Therapeutics

Cathie Wood looks for stocks in the doldrums, as long as the company has a bright long-term outlook. She recently added to positions in two of her favorite companies, which are innovating in the healthcare industry.

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Teladoc Health, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - TDOC

Teladoc Health's board of directors announced the departure of its CEO. Shares of Teladoc have lost nearly half their value since the company's initial public offering in 2015.

Teladoc Health's CEO Is Gone. Is It Time to Buy the Beaten-Down Stock?

Teladoc CEO Jason Gorevic is leaving the company. The company's CFO will take over in the short term, while the board seeks a new long-term CEO.

Why Teladoc Health Stock Took a Spill but Got Back Up Today

Teladoc Health (NYSE: TDOC ) stock is a hot topic on Friday as investors react to news of CEO Jason Gorevic stepping down. Taking over for Gorevice is Chief Financial Officer Mala Murthy.

TDOC Stock Is Down 95% Since 2021. Now the Teladoc CEO Is Leaving.

Teladoc Health on Friday announced the sudden departure of CEO Jason Gorevic

Teladoc CEO departs the company, CFO to serve as interim head

Shares of Teladoc Health Inc. were set to bounce slightly off an eight-year low on Friday, after the telehealth provider said its long-time chief executive, Jason Gorevic, was leaving the company, effective immediately.

Teladoc's long-time CEO is out after the stock hits an 8-year low

PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic's permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company's Chief Financial Officer since 2019, and she will continue serving in this role during this transition period.

Teladoc Health Board of Directors Announces Leadership Transition

Novavax

Teladoc's position in the growing telemedicine industry could help it turn things around. Novavax's only approved product is going nowhere and its pipeline has too little to offer.

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

CVS Health

Hims & Hers Health

The healthcare industry is experiencing extraordinary rapid terrain evolution as advancement meets necessity. Investors are focusing on disruptive businesses during this wave of change.

News for Teladoc Stock (TDOC)